stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Return on assets
NeoGenomics, Inc.'s return on assets over the twelve months to 30 September 2026 was −2.35%, up 4.9 percentage points from fiscal 2025 (−7.21%). Over the past ten years it has ranged from −8.95% (fiscal 2016) to 1.43% (fiscal 2018); the current reading is higher than 27% of that period. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −7.21% | (2.47) |
| FY2024 | −4.74% | 0.40 |
| FY2023 | −5.14% | 2.85 |
| FY2022 | −7.99% | (7.41) |
| FY2021 | −0.58% | (1.07) |
| FY2020 | 0.49% | (0.83) |
| FY2019 | 1.32% | (0.11) |
| FY2018 | 1.43% | 4.64 |
| FY2017 | −3.21% | 5.74 |
| FY2016 | −8.95% | (7.72) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| VCYT Veracyte, Inc. compare | 8.63% |
| FRNM Freenome, Inc compare | −0.86% |
| NEO NeoGenomics, Inc. | −2.35% |
| CSTL Castle Biosciences, Inc. compare | −4.03% |
| OPK OPKO Health, Inc. compare | −7.64% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| WGS GeneDx Holdings Corp. compare | −22.5% |
| PSNL Personalis, Inc. compare | −44.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement